Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Fiche publication
Date publication
février 2023
Journal
Breast (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr COUDERT Bruno, Dr LADOIRE Sylvain, Dr DESMOULINS Isabelle, Dr HENNEQUIN Audrey, Dr MAYEUR Didier
Tous les auteurs :
Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S
Lien Pubmed
Résumé
Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course. In view of the paucity of current literature, we questioned the usefulness of taxane rechallenge in a population of patients previously treated with taxanes in a metastatic setting.
Mots clés
Breast cancer, Chemotherapy, Docetaxel, Metastatic cancer, Paclitaxel, Rechallenge, Taxanes
Référence
Breast. 2023 02 4;68:149-156